Document is current
Any future updates will be listed below
-
Authors
Zaigham, Suneela
Christensson, Anders
Wollmer, Per
Engström, Gunnar
-
Funding
Funding for this research was provided by:
Hjärt-Lungfonden (2016-0315)
- License Information
-
More Information
Article History
Received: 9 October 2019
Accepted: 5 March 2020
First Online: 8 April 2020
Ethics approval and consent to participate
: The Health Service Authority of Malmö approved and funded the screening program. The linkage with the cause of death and patient registers was approved by the Regional ethics committee at Lund University. LU 2004–85; Written consent was not available at the time the study was conducted, however verbal consent was taken for all participants included in the study. Advertisements in newspapers were later published to inform about the studies and give participants the possibility to opt-out. The procedures were approved by the regional ethics committee at Lund university (2004–85).
: Not applicable.
: PW reports grants from Swedish Heart and Lung Foundation during the conduct of the study; personal fees from AstraZeneca, personal fees from Chiesi Pharma outside the submitted work. In addition, PW has a patent Device and method for pulmonary function measurement issued.SZ, AC and GE have no competing interests to disclose.
